Researcher in lab

Find clinical trials

Our clinical trial portfolio is one of the largest in the country. We have more than 700 clinical trials open across 30 clinical units.

Find Melbourne Sexual Health Centre research studies and clinical trials
Clear filter
637 clinical trials found
Clinical trials

076A301 SOS-AMI

Multi-center, double-blind, randomized, placebo-controlled, parallel-group study to evaluate the efficacy and safety of self-administered subcutaneous selatogrel for prevention of all-cause death and treatment of acute myocardial infarction in subjects with a recent history of acute myocardial infarction (NCT04957719)

The purpose of this study is to assess the clinical efficacy of selatogrel when self-administered upon occurrence of symptoms suggestive of an acute myocardial infarction (AMI) in participants at risk of having a recurrent AMI.
Currently recruiting

20007A

Interventional, randomized, double-blind, parallel-group, placebo-controlled study of add-on eptinezumab treatment to brief educational intervention for the preventive treatment of migraine in patients with dual diagnosis of migraine and medication overuse headache (NCT05452239)

No longer recruiting

20180257

A Phase 1b Open-label Study to Investigate the Safety and Pharmacokinetics of Administration of Subcutaneous Blinatumomab for the Treatment of Adults with Relapsed or Refractory B cell Precursor Acute Lymphoblastic Leukemia (R/R B-ALL) (NCT04521231)

Currently recruiting

2802-CL-0101

First-in-Human, Phase 1 Study to Assess the Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of a Single-Induction Dose of convertibleCAR™-T Cells Armed with MicAbody™ Protein (ASP2802) Followed by Maintenance Booster Doses of the MicAbody Protein in Patients with CD20 Positive Refractory or Relapsed B-Cell Malignancies (Astellas) (NCT06248086)

Currently recruiting

2SHOTS

2-fraction Stereotactic ultra-HypOfractionated radiation Therapy of the proState (ACTRN12625000198426)

Currently recruiting

77242113PSO3001

A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants with Moderate to Severe Plaque Psoriasis (NCT06095115)

No longer recruiting

77242113PSO3004

A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis (NCT06220604)

No longer recruiting

80948543LYM1001

A Phase 1, First-in-human Study of JNJ-80948543, a T-cell Redirecting Antibody, in Participants with NHL and CLL (NCT05424822)

Currently recruiting

87801493LYM1001

A Phase 1, First-in-human Study of JNJ-87801493 in Combination with CD3 T-Cell Engagers in Participants with Relapsed/Refractory B-cell Non-Hodgkin Lymphoid Malignancies (NHLs) (NCT06139406)

Currently recruiting

90014496LYM1001

A Phase 1b Multicenter, Open-label, Study of JNJ-90014496, an Autologous CD19/CD20 Bi-specific CAR-T Cell Therapy in Adult Participants with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (NCT05421663)

Currently recruiting

A9-3408-01

A Phase 1-1b Study to Evaluate the Safety, Efficacy and Dosimetry of [225Ac]Ac-A9-3408 in Subjects with Unresectable or Metastatic Melanoma Expressing MC1R

This is a multicenter, open-label Phase 1-1b study of [225Ac]Ac-A9-3408 in subjects with unresectable or metastatic melanoma. The goal of this trial is to see if this investigational drug is safe for adult patients with melanoma that has spread to other parts of the body or cannot be removed by surgery. It will also see if this investigational drug can shrink melanoma tumours in the body.
Currently recruiting

ABBVIE

An open-label extension of Study M15-741 to evaluate the safety and tolerability of 24-hour daily exposure of continuous subcutaneous infusion of ABBV-951 in subjects with Parkinson's disease (NCT04379050)

No longer recruiting

ABC Bicuspid Study

A Prospective Cohort Study of Bicuspid Case Selection and Valve Sizing using the ABC Bicuspid Sizing Algorithm for Sapien 3 Balloon Expandable Valve

To evaluate the clinical outcomes of patients with bicuspid aortic stenosis treated with TAVI using the Sapien 3 valve based on the ABC sizing app
Currently recruiting

ABC-X

A phase II, open label, randomised trial of ipilimumab and nivolumab with concurrent intracranial stereotactic radiotherapy versus ipilimumab and nivolumab alone in patients with melanoma brain metastases (NCT03340129)

Currently recruiting

ABIVAX Induction

A randomized, double-blind, placebo-controlled, multicenter phase III study to evaluate the efficacy and safety of ABX464 once daily for induction treatment in subjects with moderately to severely active ulcerative colitis (NCT05507203)

Currently recruiting

ABIVAX Maintenance

A randomized, double-blind, multicenter phase III study to evaluate the long-term efficacy and safety of ABX464 25 mg or 50 mg once daily as a maintenance therapy in subjects with moderately to severely active ulcerative colitis. (NCT05535946)

Currently recruiting

ABP-20001

A Randomized, Multicenter, Double-Blind, Placebo-Controlled, Phase 2 Study of ABP-450 (prabotulinumtoxinA) Purified Neurotoxin Complex for the Prevention of Migraine Headache (NCT05016661)

No longer recruiting

ABP-20002

A Randomized, Multicenter, Double-Blind, Phase 2 Extension Study of ABP-450 (prabotulinumtoxinA) Purified Neurotoxin Complex for the Prevention of Migraine Headache (NCT05016661)

No longer recruiting

AC220-167

A Phase 2, Multicenter, Randomized, Open-label Trial to Evaluate Safety and Efficacy of Two Dose Levels of Quizartinib as Maintenance for Adult Patients with Newly Diagnosed FLT3-ITD + Acute Myeloid Leukemia in Complete Remission [Comparison of Two Dose Levels of Quizartinib as Maintenance in FLT3-ITD + Acute Myeloid Leukemia Patients in Complete Remission] (NCT06824168)

This clinical two-arm trial is designed to evaluate two doses of quizartinib (30mg/day or 60mg/day) as maintenance therapy after induction/consolidation in participants with FMS-like tyrosine kinase 3 (FLT3)-internal tandem duplication (ITD) (+) acute myeloid leukemia (AML) in first complete remission (CR) who have not received allogeneic hematopoietic stem cell transplantation (allo-HSCT).
Coming soon

ACEMID

Australian Centre of Excellence in Melanoma Imaging & Diagnosis (ACEMID) Cohort Study (ACTRN12619001706167)

Currently recruiting
1 2 3